Form 8-K · Current report
Quest Diagnostics 8-K, filed Jul 23, 2026
- Filed
- CIK
- 0001022079
- Accession no.
- 0001022079-26-000067
Summary
Quest Diagnostics reported second-quarter 2026 net revenues of $3.04 billion, up 10.2% from a year earlier, and adjusted diluted EPS of $3.12, up 19.1%, and raised its full-year 2026 revenue and EPS guidance. CEO Jim Davis attributed the growth to organic revenue increases across physician, hospital, and consumer channels.
Key points
- Second-quarter 2026 net revenues were $3.043 billion, up 10.2% from a year earlier, with 10.0% organic revenue growth.
- Reported diluted EPS was $2.84, up 15.0%, and adjusted diluted EPS was $3.12, up 19.1%.
- Full-year 2026 revenue guidance was raised to $11.95–$12.05 billion, with adjusted diluted EPS guidance of $11.05–$11.25.
- New York State approved Quest's Haystack MRD test, and Quest became the largest reference lab to use Flatiron Health's OncoEMR Molecular Profiling Integration platform for select cancer tests, starting with a pilot with American Oncology Network.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition On July 23, 2026, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. Item 9.01. Financial Statements and Exhibits d. Exhibit 99.1 Press release of Quest Diagnostics Incorporated dated July 23, 2026, announcing, among other things, its results for the quarter ended June 30, 2026. 104 The cover page from this current report on Form 8-K, formatted in Inline XBRL. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.